[1]
|
Hughes, A.J., Daniel, S.E., Kilford, L., et al. (1992) Accuracy of Clinical Diagnosis of Idiopathic Parkinson’s Disease: A Clinic-Pathological Study of 100 Cases. Journal of Neurology, Neurosurgery and Psychiatry, 55, 181-184.
https://doi.org/10.1136/jnnp.55.3.181
|
[2]
|
Scherfler, C., Schwarz, J., Antonini, A., et al. (2007) Role of DAT-SPECT in the Diagnostic Work up of Parkinsonism. Movement Disorders, 22, 1229-1238.
https://doi.org/10.1002/mds.21505
|
[3]
|
Aquino, C.C. and Fox, S.H. (2015) Clinical Spectrum of Levodopa-Induced Complications. Movement Disorders, 30, 80-89. https://doi.org/10.1002/mds.26125
|
[4]
|
Encarnacion, E.V. and Hauser, R.A. (2008) Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments. European Neurology, 60, 57-66. https://doi.org/10.1159/000131893
|
[5]
|
Stocchi, F. (2009) The Hypothesis of the Genesis of Motor Complications and Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease. Parkinsonism and Related Disorders, 15, S9-S15.
https://doi.org/10.1016/S1353-8020(09)70005-7
|
[6]
|
Stocchi, F., Tagliati, M. and Olanow, C.W. (2008) Treatment of Levodopa-Induced Motor Complications. Movement Disorders, 23, S599-S612.
https://doi.org/10.1002/mds.22052
|
[7]
|
Nyholm, D. (2012) Duodopa Treatment for Advanced Parkinson’s Disease: A Review of Efficacy and Safety. Parkinsonism and Related Disorders, 18, 916-929.
https://doi.org/10.1016/j.parkreldis.2012.06.022
|
[8]
|
Antonini, A., Isaias, M., Canesi, M., et al. (2007) Duodenal Levodopa Infusion for Advanced Parkinson’s Disease: 12-Month Treatment Outcome. Movement Disorders, 22, 1145-1149. https://doi.org/10.1002/mds.21500
|
[9]
|
Nyholm, D., Nilsson Remahl, A.I., Dizdar, N., et al. (2005) Duodenal Levodopa Infusion Monotherapy vs Oral Polypharmacy in Advanced Parkinson’s Disease. Neurology, 64, 216-223. https://doi.org/10.1212/01.WNL.0000149637.70961.4C
|
[10]
|
Schrempf, W., Brandt, M.D., Storch, A., et al. (2014) Sleep Disorders in Parkinson’s Disease. Journal of Parkinson’s Disease, 4, 211-221.
|
[11]
|
Goldstein, D.S. (2014) Dysautonomia in Parkinson’s Disease. Comprehensive Physiology, 4, 805-826. https://doi.org/10.1002/cphy.c130026
|
[12]
|
Cury, R.G., Galhardoni, R., Fonoff, E.T., et al. (2016) Sensory Abnormalities and Pain in Parkinson Disease and Its Modulation by Treatment of Motor Symptoms. European Journal of Pain, 20, 151-165. https://doi.org/10.1002/ejp.745
|
[13]
|
Blonder, L.X. and Slevin, J.T. (2011) Emotional Dysfunction in Parkinson’s Disease. Behavioural Neurology, 24, 201-217. https://doi.org/10.1155/2011/143857
|
[14]
|
Emre, M., Ford, P.J., Bilgic, B. and Uc, E.Y. (2014) Cognitive Impairment and Dementia in Parkinson’s Disease: Practical Issues and Management. Movement Disorders, 29, 663-672. https://doi.org/10.1002/mds.25870
|
[15]
|
Prakash, K.M., Nadkarni, N.V., Lye, W.K., Yong, M.-H. and Tan, E.-K. (2016) The Impact of Non-Motor Symptoms on the Quality of Life of Parkinson’s Disease Patients: A Longitudinal Study. European Journal of Neurology, 23, 854-860.
https://doi.org/10.1111/ene.12950
|
[16]
|
Pellicano, C., Assogna, F., Cravello, L., et al. (2015) Neuropsychiatric and Cognitive Symptoms and Body Side of Onset of Parkinsonism in Unmedicated Parkinson’s Disease Patients. Parkinsonism and Related Disorders, 21, 1096-1100.
https://doi.org/10.1016/j.parkreldis.2015.07.002
|
[17]
|
Aarsland, D. and Kurz, M.W. (2010) The Epidemiology of Dementia Associated with Parkinson’s Disease. Journal of the Neurological Sciences, 289, 18-22.
https://doi.org/10.1016/j.jns.2009.08.034
|
[18]
|
Giladi, N., Treves, T.A., Paleacu, D., et al. (2000) Risk Factors for Dementia, Depression and Psychosis in Long-Standing Parkinson’s Disease. Journal of Neural Transmission, 107, 59-71. https://doi.org/10.1007/s007020050005
|
[19]
|
Riedel, O., Klotsche, J., Spottke, A., et al. (2008) Cognitive Impairment in 873 Patients with Idiopathic Parkinson’s Disease. Results from the German Study Group on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). Journal of Neurology, 255, 255-264. https://doi.org/10.1007/s00415-008-0720-2
|
[20]
|
Wang, Q., Zhang, Z., Li, L., Wen, H. and Xu, Q. (2014) Assessment of Cognitive Impairment in Patients with Parkinson’s Disease: Prevalence and Risk Factors. Clinical Intervention in Aging, 12, 275-281.
|
[21]
|
Anang, J.B., Gagnon, J.F., Bertrand, J.A., et al. (2014) Predictors of Dementia in Parkinson Disease: A Prospective Cohort Study. Neurology, 83, 1253-1260.
https://doi.org/10.1212/WNL.0000000000000842
|
[22]
|
Fanciulli, A., Strano, S., Colosimo, C., Caltagirone, C., Spalletta, G. and Pontieri, F.E. (2013) The Potential Prognostic Role of Cardiovascular Autonomic Failure in α-Synucleinopathies. European Journal of Neurology, 20, 231-235.
https://doi.org/10.1111/j.1468-1331.2012.03819.x
|
[23]
|
Amboni, M., Barone, P. and Hausdorff, J.M. (2013) Cognitive Contribution to Gait and Falls: Evidence and Implications. Movement Disorders, 28, 1520-1533.
https://doi.org/10.1002/mds.25674
|
[24]
|
Erro, R., Santangelo, G., Picillo, M., et al. (2013) Side of Onset Does Not Influence Cognition in Newly Diagnosed Untreated Parkinson’s Disease Patients. Parkinsonism and Related Disorders, 19, 256-259.
https://doi.org/10.1016/j.parkreldis.2012.10.020
|
[25]
|
Verreyt, N., Nys, G.M., Santens, P. and Vingerhoets, G. (2011) Cognitive Differences between Patients with Left-Sided and Right-Sided Parkinson’s Disease: A Review. Neuropsychological Reviews, 21, 405-424.
https://doi.org/10.1007/s11065-011-9182-x
|
[26]
|
Siepel, F.J., Bronnick, K.S., Booij, J., et al. (2014) Cognitive Executive Impairment and Dopaminergic Deficits in De Novo Parkinson’s Disease. Movement Disorders, 29, 1802-1808. https://doi.org/10.1002/mds.26051
|
[27]
|
Monchi, O., Petrides, M., Doyon, J., Postuma, R.B., Worsley, K. and Dagher A. (2004) Neural Bases of Set-Shifting Deficits in Parkinson’s Disease. Journal of Neuroscience, 24, 702-710. https://doi.org/10.1523/JNEUROSCI.4860-03.2004
|
[28]
|
Monchi, O., Petrides, M., Strafella, A.P., Worsley, K.J. and Doyon, J. (2006) Functional Role of the Basal Ganglia in the Planning and Execution of Actions. Annals of Neurology, 59, 257-264. https://doi.org/10.1002/ana.20742
|
[29]
|
Provost, J.S., Petrides, M. and Monchi, O. (2010) Dissociating the Role of the Caudate Nucleus and Dorsolateral Prefrontal Cortex in the Monitoring of Events within Human Working Memory. European Journal of Neuroscience, 32, 873-880.
https://doi.org/10.1111/j.1460-9568.2010.07333.x
|
[30]
|
Seger, C.A., Peterson, E.J., Cincotta, C.M., Lopez-Paniagua, D. and Anderson, C.W. (2010) Dissociating the Contributions of Independent Corticostriatal Systems to Visual Categorization Learning through the Use of Reinforcement Learning Modeling and Granger Causality Modeling. Neuroimage, 50, 644-656.
https://doi.org/10.1016/j.neuroimage.2009.11.083
|
[31]
|
Jellinger, K.A. (2010) Neuropathology in Parkinson’s Disease with Mild Cognitive Impairment. Acta Neuropathologica, 120, 829-830.
https://doi.org/10.1007/s00401-010-0755-1
|
[32]
|
Adler, C.H., Connor, D.J., Hentz, J.G., et al. (2010) Incidental Lewy Body Disease: Clinical Comparison to a Control Cohort. Movement Disorders, 25, 642-646.
https://doi.org/10.1002/mds.22971
|
[33]
|
MacDonald, P.A., MacDonald, A.A., Seergobin, K.N., et al. (2011) The Effects of Dopamine Therapy on the Ventral and Dorsal Striatum-Mediated Cognition in Parkinson’s Disease: Support from Functional MRI. Brain, 134, 1447-1463.
https://doi.org/10.1093/brain/awr075
|
[34]
|
Braak, H., Del Tredici, K., Rub, U., de Vos, R.A.I., Jansen Steur, E.N.H. and Braak, E. (2003) Staging of Brain Pathology Related to Sporadic Parkinson’s Disease. Neurobiology of Aging, 24, 197-211. https://doi.org/10.1016/S0197-4580(02)00065-9
|
[35]
|
Francis, P.T. and Perry, E.K. (2007) Cholinergic and Other Neurotransmitter Mechanisms in Parkinson’s Disease, Parkinson’s Disease Dementia, and Dementia with Lewy Bodies. Movement Disorders, 22, S351-S357.
https://doi.org/10.1002/mds.21683
|
[36]
|
Kehagia, A.A., Barker, R.A. and Robbins, T.W. (2010) Neuropsychological and Clinical Heterogeneity of Cognitive Impairment in Patients with Parkinson’s Disease. The Lancet Neurology, 9, 1200-1213.
https://doi.org/10.1016/S1474-4422(10)70212-X
|
[37]
|
Lewis, S.J.G., Slabosz, A., Robbins, T.W, Barker, R.A. and Owen, A.M. (2005) Dopaminergic Basis for Deficits in Working Memory but Not Attentional Set-Shifting in Parkinson’s Disease. Neuropsychologia, 43, 823-832.
https://doi.org/10.1016/j.neuropsychologia.2004.10.001
|
[38]
|
Slabosz, A., Lewis, S.J.G., Smigasiewicz, K., Szymura, B., Barker, R.A. and Owen, A.M. (2006) The Role of Learned Irrelevance in Attentional Set-Shifting Impairments in Parkinson’s Disease. Neuropsychology, 20, 578-588.
https://doi.org/10.1037/0894-4105.20.5.578
|
[39]
|
Torta, D.M.E., Castelli, L., Zibetti, M., Lopiano, L. and Geminiani, G. (2009) On the Role of Dopamine Replacement Therapy in Decision-Making, Working Memory, and Retard in Parkinson’s Disease: Does the Therapy-Dose Matter? Brain and Cognition, 71, 84-91. https://doi.org/10.1016/j.bandc.2009.04.003
|
[40]
|
Costa, A., Peppe, A., Dell’Agnello, G., et al. (2003) Dopaminergic Modulation of Visual-Spatial Working Memory in Parkinson’s Disease. Dementia and Geriatric Cognitive Disorders, 15, 55-66. https://doi.org/10.1159/000067968
|
[41]
|
Costa, A., Peppe, A., Dell’Agnello, G., Caltagirone, C. and Carlesimo, G.A. (2009) Dopamine and Cognitive Functioning in De Novo Subjects with Parkinson’s Disease: Effects of Pramipexole and Pergolide on Working Memory. Neuropsychologia, 47, 1374-1381. https://doi.org/10.1016/j.neuropsychologia.2009.01.039
|
[42]
|
Costa, A., Peppe, A., Brusa, L., Caltagiron, C., Gatto, I. and Carlesimo, G.A. (2008) Dopaminergic Modulation of Prospective Working Memory in Parkinson’s Disease. Behavioural Neurology, 19, 45-48. https://doi.org/10.1155/2008/310437
|
[43]
|
Costa, A., Peppe, A., Brusa, L., et al. (2008) Levodopa Improve Time-Based Prospective Memory in Parkinson’s Disease. Journal of the International Neuropsychological Society, 14, 601-610. https://doi.org/10.1017/S135561770808082X
|
[44]
|
Shohamy, D., Myers, C.E., Gehman, K.D., Sage, J. and Gluck, M.A. (2006) L-Dopa Impairs Learning, but Spares Generalization, in Parkinson’s Disease. Neuropsychologia, 44, 774-784. https://doi.org/10.1016/j.neuropsychologia.2005.07.013
|
[45]
|
Jahanshahi, M., Wilkinson, L., Gahir, H., Dharminda, A. and Lagnado, D.A. (2010) Medication Impairs Probabilistic Classification Learning in Parkinson’s Disease. Neuropsychologia, 48, 1096-1103.
https://doi.org/10.1016/j.neuropsychologia.2009.12.010
|
[46]
|
Feigin, A.S., Ghilardi, M.F., Carbon, M., et al. (2003) Effects f Levodopa on Motor Sequence Learning in Parkinson’s Disease. Neurology, 60, 1744-1749.
https://doi.org/10.1212/01.WNL.0000072263.03608.42
|
[47]
|
Seo, M., Beigi, M., Jahashahi, M., et al. (2010) Effects of Dopamine Medication on Sequence Learning with Stochastic Feedback in Parkinson’s Disease. Frontiers of Human Neuroscience, 4, pii: 36.
|
[48]
|
Ghilardi, M.F., Feigin, A.S., Battaglia, A., et al. (2007) L-Dopa Infusion Does Not Improve Explicit Sequence Learning in Parkinson’s Disease. Parkinsonism and Related Disorders, 13, 146-151. https://doi.org/10.1016/j.parkreldis.2006.08.006
|
[49]
|
Frank, M.J., Seeberger, L.C. and O’Reilly, R.C. (2004) By Carrot or By Stick: Cognitive Reinforcement Learning in Parkinsonism. Science, 306, 1940-1943.
https://doi.org/10.1126/science.1102941
|
[50]
|
Evans, A.H., Lawrence, A.D., Potts, J., et al. (2006) Relationship between Impulsive Sensation Seeking Traits, Smoking, Alcohol and Caffeine Intake, and Parkinson’s Disease. Journal of Neurology, Neurosurgery and Psychiatry, 77, 317-321.
https://doi.org/10.1136/jnnp.2005.065417
|
[51]
|
Sohn, M.H., Ursu, S., Anderson, J.R., Stenger, V.A. and Carter, C.S. (2000) The Role of Prefrontal Cortex and Posterior Parietal Cortex in Task Switching. Proceedings of the National Academy of Sciences USA, 97, 13448-13453.
https://doi.org/10.1073/pnas.240460497
|
[52]
|
Dias, R., Robbins, T.W. and Roberts, A.C. (1996) Dissociation in Prefrontal Cortex of Affective and Attentional Shifts. Nature, 380, 69-72.
https://doi.org/10.1038/380069a0
|
[53]
|
Graef, S., Biele, G., Krugel, L.K., et al. (2010) Differential Influence of Levodopa on Reward-Based Learning in Parkinson’s Disease. Frontiers of Human Neuroscience, 4, 169. https://doi.org/10.3389/fnhum.2010.00169
|
[54]
|
Tomer, R., Aharon-Peretz, J. and Tsitrinbaum, Z. (2007) Dopamine Asymmetry Interacts with Medication to Affect Cognition in Parkinson’s Disease. Neuropsychologia, 45, 357-367. https://doi.org/10.1016/j.neuropsychologia.2006.06.014
|
[55]
|
Kish, S.J., Shannak, K. and Ornykiewicz, O. (1988) Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson’s Disease. Pathophysiologic and Clinical Implication. New England Journal of Medicine, 318, 876-880.
https://doi.org/10.1056/NEJM198804073181402
|
[56]
|
Fearnley, J.M. and Lees, A.J. (1991) Ageing and Parkinson’s Disease: Substantia Nigra Regional Selectivity. Brain, 114, 2283-2301.
https://doi.org/10.1093/brain/114.5.2283
|
[57]
|
Djaldetti, R., Lorberboym, M., Karmon, Y., Treves, T.A., Ziv, I. and Melamed, E. (2011) Residual Striatal Dopaminergic Nerve Terminals Nerve Terminals in Very Long-Standing Parkinson’s Disease: A Single Photon Emission Computed Tomography Imaging Study. Movement Disorders, 26, 327-330.
https://doi.org/10.1002/mds.23380
|
[58]
|
MacDonald, P.A. and Monchi, O. (2011) Differential Effect of Dopaminergic Therapies on Dorsal and Ventral Striatum in Parkinson’s Disease: Implications for Cognitive Function. Parkinson’s Disease, 2011, Article ID: 522743.
|
[59]
|
Zweig, R.M., Disbrow, E.A. and Javalkar, V. (2016) Cognitive and Psychiatric Disturbances in Parkinsonian Syndromes. Neurologic Clinics, 34, 235-246.
https://doi.org/10.1016/j.ncl.2015.08.010
|
[60]
|
Wright, B.A. and Waters, C.H. (2013) Continuous Dopaminergic Delivery to Minimize Motor Complications in Parkinson’s Disease. Expert Review of Neurotherapeutics, 13, 719-729. https://doi.org/10.1586/ern.13.47
|
[61]
|
Ferreira, J.J., Katzenschlager, R., Bloem, B.R., et al. (2013) Summary of the Recommendations of the EFNS/MDS-ES Review on Therapeutic Management of Parkinson’s Disease. European Journal of Neurology, 20, 5-15.
https://doi.org/10.1111/j.1468-1331.2012.03866.x
|
[62]
|
Grandas, F. (2013) Subcutaneous Infusion of Apomorphine: A Reappraisal of Its Therapeutic Efficacy in Advanced Parkinson’s Disease. Expert Review of Neurotherapeutics, 13, 1343-1353. https://doi.org/10.1586/14737175.2013.839235
|
[63]
|
Wu, B., Han, L., Sun, B.M., Hu, X.-W. and Wang, X.-P. (2014) Influence of Deep Brain Stimulation of the Subthalamic Nucleus on Cognitive Functions in Patients with Parkinson’s Disease. Neuroscience Bullettin, 30, 153-161.
https://doi.org/10.1007/s12264-013-1389-9
|
[64]
|
Antonini, A., Yegin, A., Preda, C., Bergmann, L. and Poewe, W. (2015) Global Long-Term Study on Motor and Non-Motor Symptoms and Safety of Levodopa-Carbidopa Intestinal Gel in Routine Care of Advanced Parkinson’s Disease Patients; 12-Month Interim Outcomes. Parkinsonism and Related Disorders, 21, 231-235. https://doi.org/10.1016/j.parkreldis.2014.12.012
|
[65]
|
Devos, D. and French Duodopa Study Group (2009) Patient Profile, Indications, Efficacy, and Safety of Duodenal Levodopa Infusion in Advanced Parkinson’s Disease. Movement Disorders, 24, 993-1000. https://doi.org/10.1002/mds.22450
|
[66]
|
Busk, K. and Nyholm, D. (2012) Long-Term 24-H Levodopa/Carbidopa Gel Infusion in Parkinson’s Disease. Parkinsonism and Related Disorders, 18, 1000-1001.
https://doi.org/10.1016/j.parkreldis.2012.04.010
|
[67]
|
Sanchez-Castaneda, C., Campdelacreu, J., Mirò, J., Juncadella, M., Jaumà, S. and Calopa, M. (2010) Cognitive Improvement after Duodenal Levodopa Infusion in Cognitively Impaired Parkinson’s Disease Patients. Progress in Neuro-psychopharmacology and Biological Psychiatry, 34, 250-251.
https://doi.org/10.1016/j.pnpbp.2009.10.021
|
[68]
|
Honig, H., Antonini, A., Martinez-Martin, P., et al. (2009) Intrajejunal Levodopa Infusion in Parkinson’s Disease: A Pilot Multicenter Study of Effects on Nonmotor Symptoms and Quality of Life. Movement Disorders, 24, 1468-1474.
https://doi.org/10.1002/mds.22596
|
[69]
|
Zibetti, M., Merola, A., Ricchi, V., et al. (2013) Long-Term Duodenal Levodopa Infusion in Parkinson’s Disease: A 3-Year Motor and Cognitive Follow-Up Study. Journal of Neurology, 260, 105-114. https://doi.org/10.1007/s00415-012-6597-0
|
[70]
|
Olanow, C.W. and Shapira, A.H. (2013) Therapeutic Prospects for Parkinson’s Disease. Annals of Neurology, 74, 337-347. https://doi.org/10.1002/ana.24011
|
[71]
|
Olanow, C.W., Kieburtz, K., Odin, P., et al. (2014) Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Randomized, Controlled, Double-Blind, Double-Dummy Study. The Lancet Neurology, 13, 141-149. https://doi.org/10.1016/S1474-4422(13)70293-X
|
[72]
|
Merola, A., Zibetti, M., Angrisano, S., Rizzi, L., Lanotte, M. and Lopiano, L. (2011) Comparison of Subthalamic Nucleus Deep Brain Stimulation and Duodopa in the Treatment of Advanced Parkinson’s Disease. Movement Disorders, 26, 664-670.
https://doi.org/10.1002/mds.23524
|